{"id":"botulinum-toxin-type-a-900kda","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Neck pain"},{"rate":"5–10","effect":"Injection site pain or bruising"},{"rate":"5–15","effect":"Muscle weakness (localized)"},{"rate":"1–5","effect":"Ptosis (eyelid drooping)"},{"rate":"1–3","effect":"Diplopia (double vision)"},{"rate":"1–5","effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25 (synaptosome-associated protein of 25 kDa), preventing acetylcholine vesicles from fusing with the presynaptic membrane. This results in flaccid paralysis of the injected muscle that typically lasts 3–4 months. The 900 kDa form includes associated proteins that stabilize the toxin complex.","oneSentence":"Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:30.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Strabismus"},{"name":"Chronic migraine"},{"name":"Severe primary axillary hyperhidrosis"},{"name":"Glabellar lines (cosmetic)"},{"name":"Crow's feet (cosmetic)"},{"name":"Forehead lines (cosmetic)"}]},"trialDetails":[{"nctId":"NCT04871451","phase":"PHASE2","title":"Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia","status":"COMPLETED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-07-27","conditions":"Cervical Dystonia","enrollment":51},{"nctId":"NCT04849988","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia","status":"COMPLETED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-03-29","conditions":"Cervical Dystonia","enrollment":61},{"nctId":"NCT00761592","phase":"PHASE4","title":"Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-07","conditions":"Blepharospasm","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®"],"phase":"marketed","status":"active","brandName":"Botulinum Toxin Type A 900kDa","genericName":"Botulinum Toxin Type A 900kDa","companyName":"Allergan","companyId":"allergan","modality":"Biologic","firstApprovalDate":"","aiSummary":"Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}